Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice

References

• Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult. Scler. 10(5), 589–595 (2004).
   PubMed Web of Science ®Google Scholar
• Hemmett L, Holmes J, Barnes M, Russell N. What drives quality of life in multiple sclerosis? QJM 97(10), 671–676 (2004).
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C, González-Segura D, Vila C. Spasticity in multiple sclerosis: results of a patient survey. Int. J. Neurosci. 123(6), 400–408 (2013).
   PubMed Web of Science ®Google Scholar
• Stevenson VL. Rehabilitation in practice: spasticity management. Clin. Rehabil. 24(4), 293–304 (2010).
   PubMed Web of Science ®Google Scholar
• Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst. Rev. (4), CD001332 (2003).
   PubMedGoogle Scholar
• Flachenecker P, Henze T, Hengsbach M, Ehlken B, Zettl UK. Spasticity in multiple sclerosis – a cross-sectional survey in Germany. Mult. Scler. 18, S21 (2012).
   Google Scholar
• Berger T. Multiple sclerosis spasticity daily management: retrospective data from Europe. Expert Rev. Neurother. 13(3 Suppl. 1), 3–7 (2013).
   Google Scholar
• Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys. Ther. 67(2), 206–207 (1987).
   PubMed Web of Science ®Google Scholar
• Fleuren JF, Voerman GE, Erren-Wolters CV et al. Stop using the Ashworth Scale for the assessment of spasticity. J. Neurol. Neurosurg. Psychiatry 81(1), 46–52 (2010).
   PubMed Web of Science ®Google Scholar
• Hobart JC, Riazi A, Thompson AJ et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 129(Pt 1), 224–234 (2006).
   PubMedGoogle Scholar
• Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365(6441), 61–65 (1993).
   PubMed Web of Science ®Google Scholar
• Di Marzo V. The endocannabinoid system for the development of new drugs for spasticity. Drugs Fut. 32(4), 341–351 (2007).
   Web of Science ®Google Scholar
• Cota D, Tschöp MH, Horvath TL, Levine AS. Cannabinoids, opioids and eating behavior: the molecular face of hedonism? Brain Res. Rev. 51(1), 85–107 (2006).
   PubMedGoogle Scholar
• Perez J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today (Barc). 42(8), 495–503 (2006).
   PubMed Web of Science ®Google Scholar
• Huestis MA, Henningfield JE, Cone EJ. Blood cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking marijuana. J. Anal. Toxicol. 16(5), 276–282 (1992).
   PubMed Web of Science ®Google Scholar
• Stott CG, Wright S, Guy GW. Comparison of pharmacokinetic profiles of inhaled delta-9-tetrahydrocannabinol (THC) from smoked cannabis with Sativex® oromucosal spray in humans, implications for possible symptomatic treatment in multiple sclerosis. Eur. J. Neurol. 15 (Suppl. 3), 222–390 (2008)
   Google Scholar
• Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler. 10(4), 434–441 (2004).
   PubMed Web of Science ®Google Scholar
• Collin C, Davies P, Mutiboko IK, Ratcliffe S; Sativex Spasticity in MS Study Group. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol. 14(3), 290–296 (2007).
   PubMed Web of Science ®Google Scholar
• Collin C, Ehler E, Waberzinek G et al. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res. 32(5), 451–459 (2010).
   PubMed Web of Science ®Google Scholar
• Novotna A, Mares J, Ratcliffe S et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®)), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol. 18(9), 1122–1131 (2011).
   PubMed Web of Science ®Google Scholar
• García-Merino A. Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain. Expert Rev. Neurother. 13(3 Suppl. 1), 9–13 (2013).
   PubMed Web of Science ®Google Scholar
• Flachenecker P. A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany. Expert Rev. Neurother. 13(3 Suppl. 1), 15–19 (2013).
   Google Scholar
• Aragona M, Onesti E, Tomassini V et al. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin. Neuropharmacol. 32(1), 41–47 (2009).
   PubMed Web of Science ®Google Scholar